Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Cancer Immunology, Immunotherapy

Volumn 62, Issue 8, 2013, Pages 1293-1301

  Morse, Michael A ^a,c   Chaudhry, Arvind ^b   Gabitzsch, Elizabeth S ^e   Hobeika, Amy C ^a   Osada, Takuya ^a   Clay, Timothy M ^f   Amalfitano, Andrea ^d   Burnett, Bruce K ^c   Devi, Gayathri R ^a   Hsu, David S ^a,c   Xu, Younong ^e   Balcaitis, Stephanie ^e   Dua, Rajesh ^e   Nguyen, Susan ^e   Balint Jr , Joseph P ^e   Jones, Frank R ^e   Lyerly, H Kim ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Medical Oncology Associates   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e Etubics Corporation   (United States)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Ad5 vector; CEA; Cell mediated immunity; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; E1 DELETED ADENOVIRUS SUBTYPE 5 BASED VECTOR; E2B DELETED ADENOVIRUS SUBTYPE 5 BASED VECTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; INJECTION SITE REACTION; MALE; METASTATIC COLORECTAL CANCER; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADULT; AGED; ANTIBODIES, NEUTRALIZING; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880916286     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1400-3     Document Type: Article

References (46)

1. Kantoff P, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
2. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099-1105
3. Vergati M, Intrivici C, Huen N-Y, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol pii:596432
4. Palena C, Schlom J (2010) Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol pii:380697
5. Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849-862
6. Campos SK, Barry MA (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7:189-204
7. Tatsis N, Ertl HCJ (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616-629
8. Seregin SS, Amalfitano A (2009) Overcoming pre-existing Adenovirus immunity by genetic engineering of Adenovirus-based vectors. Expert Opin Biol Ther 9:1-11
9. Nwanegbo E, Vardas E, Gao W et al (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11:351-357
10. Gabitzsch ES, Jones FR (2011) New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations. J Clin Cell Immunol. doi: 10.4172/2155-9899.S4-001
11. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72:926-933
12. Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR (2010) Anti-tumor immunity despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 59:1131-1135
13. Gabitzsch ES, Xu Y, Balcaitis S, Balint JP Jr, Jones FR (2011) An Ad5 [E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 18:326-335
14. Gabitzsch ES, Xu Y, Balint JP Jr, Balcaitis S, Sanders-Beer B, Jones FR (2011) Induction and comparison of SIV immunity in Ad5 Naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine 29:8101-8107
15. Jones FR, Gabitzsch ES, Xu Y et al (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020-7026
16. Osada T, Yang XY, Hartman ZC et al (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16:673-682
17. Gabitzsch ES, Xu Y, Yoshida LH et al (2009) A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 122:44-51
18. Gabitzsch ES, Yu X, Yoshida LH, Balint J, Amalfitano A, Jones FR (2009) Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27:6394-6398
19. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570-4577
20. Tangri S, Ishioka GY, Huang X et al (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194:833-846
21. Morse MA, Hobeika AC, Osada T et al (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120:3234-3241
22. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
23. CTEP Cancer Therapy Evaluation Program. CTCAE and CTC Website (2010) http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 10 Feb 2012
24. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207-212
25. Sanda MG, Smith DC, Charles LG et al (1999) Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate specific immune response in androgen-modulated human prostate cancer. Urology 53:260-266
26. Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632-1638
27. Gulley J, Chen AP, Dahut W et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53:109-117
28. Kaufman HL, Wang W, Manola J et al (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22:2122-2132
29. Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337
30. Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197-2207
31. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67-81
32. Morse MA, Clay TM, Hobeika AC et al (2005) Phase I study of immunization with dendritic cells modified with recombinant fowlpox encoding carcinoembryonic antigen and the triad of costimulatory molecules CD54, CD58, and CD80 in patients with advanced malignancies. Clin Cancer Res 11:3017-3024
33. Morse MA, Hobeika AC, Osada T et al (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610-618
34. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62:1009-1030
35. Amalfitano A, Parker RJ (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2:111-133
36. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A (2003) Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 14:1715-1726
37. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A (2000) Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2:250-259
38. Joshi A, Tang J, Kuzma M et al (2009) Adenovirus DNA polymerase is recognized by human CD8+ T cells. J Gen Virol 90:84-94
39. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
40. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from Cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
41. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
42. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094
43. Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679
44. Gulley JL, Arlen PM, Madan RA et al (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59:663-674
45. Gulley JL, Madan RA, Schlom J (2011) Impact of tumor volume on the potential efficacy of therapeutic vaccines. Curr Oncol 8:150-157
46. Palucka K, Ueno H, Fay J, Banchereau J (2011) Dendritic cells and immunity against cancer. J Intern Med 269:64-73